

## Press Release

### **GLYCOTOPE GmbH Presents Novel GlycoExpress™ Technology an Expression System for New Generations of Highly Active & Fully Human Biologics**

Berlin, 07.05.2004. GLYCOTOPE GmbH, a specialist for Glycobiology and Cellular Engineering has presented its novel GlycoExpress™ technology in a lecture during the Glycomics conference (CHI) in Cambridge, MA, USA.

GlycoExpress™ is a novel expression platform which allows the generation of proteins with fully human glycosylation and optimised sialylation. With this technology improved biologics with higher activity, optimized pharmacokinetics, and decreased antigenicity and immunogenicity can be produced. This technology is ideal for critical improvements of pharmaceutical protein products or for the development of a more effective new generation of biopharmaceuticals.

GlycoExpress™ is based on glycoengineered human cell lines which were generated by GLYCOTOPE's Cellular GlycoEngineering technology over the last years. These biotechnologically suitable cell lines can produce high amounts of improved recombinant proteins of interest with the aim for clinical applications.

GlycoExpress™ is not only able to generate human N-glycosylations on target proteins but also O-glycosylations and other human protein modifications. Importantly, GlycoExpress™ is an integrated system. In a first step the fully human glycosylated product with the optimal sialylation is selected from a series of different sialylated forms due to its optimal in vitro and in vivo activity, serum-half-life, antigenicity and/ or immunogenicity. In a second step the optimized biologic is produced in the same system.

"We are enthusiastic about GlycoExpress and its potential for the generation of new generations of more effective and fully human biologics. We were able to generate and optimise a fully human growth factor which has an at least 500 times higher activity than its currently available recombinant forms expressed in E.coli or yeast. The differential sialylation also allowed us to generate in another case a potent glycoprotein based vaccine for a customer. We are now starting to look for further partners exploiting this potent technology together with us for the optimisation and humanisation of various target molecules including hormones, growth factors, cytokines and antibodies", said Dr. Steffen Goletz, CEO of GLYCOTOPE.

GLYCOTOPE was founded in 2001 focusing on customized services in Protein Expression, GlycoEngineering and GlycoAnalytics. GLYCOTOPE has developed cellular and molecular glycosylation platforms and offers a full range of glycoanalytical techniques in-house and in combination with a network of specialists. Combining expertises in the fields of drug development, analytics, glycobiology, cell biology, molecular biology, biotechnology, antibody engineering and immunology GLYCOTOPE is a competent partner for the development of innovative pharmaceutical therapeutics and nutrition additives.

Enquiries:  
GLYCOTOPE GmbH  
Dr. Hans Baumeister  
Director Business Development  
Tel. +49 (0)30 941084-207, Fax +49 (0)30 941084-188  
E-mail: [hans.baumeister@glycotope.com](mailto:hans.baumeister@glycotope.com)  
[www.glycotope.com](http://www.glycotope.com)